Abstract
In this research, whole process of small-scale and pilot-scale carrier-free 177Lu production have been developed and curie-level 177Lu was achieved. Additionally, the methodology of product key quality control inspection has been developed and verified, the control standard has been established. Key indicators of the product have met or exceeded the requirements of the European Pharmacopoeia. Up to date, about 30 Ci carrier-free 177Lu product has been obtained based on this development. The carrier-free 177Lu obtained in this research has been used in nearly 20 trial parties including units for drug R & D and clinical research.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Khreish F, Eber N, Dies M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholomä M, Ezziddin S (2020) 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imag 47:721–728
Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, Zhu Z, Chen X (2020) 177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer. J Nucl Med 61:1772–1778
Gafita A, Heck MM, Rauscher I, Tauber R, Cala L, Franz C, D’Alessandria C, Retz M, Weber WA, Eiber M (2020) Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med 61:1476–1483
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I (2020) The68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Eur J Nucl Med Mol Imag 47:695–712
Yadav MP, Ballal S, Beckel M, Roesch F, Bal C (2020) [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results. EJNMMI Res 10:30
Manenti S, Groppi F, Gandini A, Gini L, Abbas K, Holzwarth U (2011) Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177g Lu in no-carrier-added form for metabolic radiotherapy. Appl Radiat Isot 69(1):37–45
Manenti S, Bonardi ML, Gini L, Groppi F (2014) Physical optimization of production by deuteron irradiation of high specific activity 177g Lu suitable for radioimmunotherapy. Nucl Med Biol 41(5):407–409
Pillai MRA, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N (2003) Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot 59:109
Knapp FF Jr, Mirzadeh S, Beets AL, Du MJ (2005) Production of therapeutic radioisotopes in the ORNL high flux isotope reactor (HFIR) for applications in nuclear medicine, oncologyand interventional cardiology. J Radioanal Nucl Chem 263:503
Kondo K, Kamio E (2002) Separation of rare earth metals with a polymeric microcapsule membrane. Desalination 144:249–254
Kamio E, Kondo K (2002) Separation and concentration of lanthanides using microcapsules containing acidic organo-phosphorus compounds as an extractant. J Chem Eng Japan 35:574–581
Lewis RE, Su F-M, Lane TA, Olewine KR, Holton PS (2003) Method and apparatus for separating ions of metallic elements in aqueous solution. United States Patent Application, PubNo.: US 2003/0152502A1
Tsuyoshi A, Ogawa H, Akiba K, Hoshi H, Kitazumi E (2000) High-speed countercurrent chromatography using a small coiled column. J Liquid Chromatogr Related Technol 23:1995–2008
Horwitza EP, McAlistera DR, Bonda AH, Barransa RE, Williamson JMA (2005) Process for the separation of 177Lu from neutron irradiated 176Yb targets. Appl Radiat Isot 63:23–36
Chinese pharmacopoeia 2020 Edition: four General Principles 1401
Chinese pharmacopoeia 2020 Edition: four General Principles 1143
Chinese pharmacopoeia 2020 Edition: four General Principles 1101
Zhuo L, Yang Y, Yue H, **ong X, Wang G, Wang H, Kan W (2022) Effective lutetium/ytterbium separation for no-carrier added lutetium-177 production. J Radioanal Nucl Chem 331:5719–5727
European pharmacopoeia 10.0: lutetium (177Lu) solution for radiolabelling, 1218–1219
Acknowledgements
This work is supported by Key R&D Project of Sichuan Science and Technology Program [grant no. 2019ZDZX0012], Nuclear Energy Development Project of State Administration of Science, Technology and Industry for National Defense [grant no. 20201192-1] and The Central Guidance for Local Science and Technology Development Projects [grant no. 202138-03].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There exists no conflict of interest in this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yang, Y., Kan, W., Zhuo, L. et al. Whole process establishment of carrier-free 177Lu production: from small-scale production to pilot-scale production. J Radioanal Nucl Chem 332, 4917–4928 (2023). https://doi.org/10.1007/s10967-023-09210-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-023-09210-x